Uniqure NV (NASDAQ:QURE) insider Christian Klemt sold 5,093 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total transaction of $102,522.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Uniqure NV (NASDAQ:QURE) opened at $19.48 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73. The stock has a market cap of $587.03, a PE ratio of -7.46 and a beta of 0.72. Uniqure NV has a fifty-two week low of $4.72 and a fifty-two week high of $21.35.

Several equities research analysts have commented on the stock. Janney Montgomery Scott assumed coverage on shares of Uniqure in a research report on Wednesday. They set a “buy” rating and a $25.00 price target on the stock. ValuEngine raised shares of Uniqure from a “sell” rating to a “hold” rating in a research report on Monday, January 1st. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised shares of Uniqure from a “sell” rating to a “hold” rating and set a $21.00 price target on the stock in a research report on Tuesday, October 24th. Finally, HC Wainwright set a $28.00 price target on shares of Uniqure and gave the stock a “buy” rating in a research report on Thursday, December 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Uniqure currently has an average rating of “Buy” and a consensus target price of $20.00.

Several hedge funds have recently modified their holdings of QURE. Mangrove Partners bought a new stake in shares of Uniqure in the 2nd quarter valued at about $247,000. JPMorgan Chase & Co. raised its holdings in shares of Uniqure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 14,659 shares during the period. OxFORD Asset Management LLP bought a new stake in shares of Uniqure in the 3rd quarter valued at about $399,000. Finally, FMR LLC raised its holdings in shares of Uniqure by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares during the period. 24.87% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Uniqure NV (QURE) Insider Christian Klemt Sells 5,093 Shares of Stock” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/uniqure-nv-qure-insider-christian-klemt-sells-5093-shares-of-stock/1797300.html.

About Uniqure

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with Analyst Ratings Network's FREE daily email newsletter.